ALNYLAM PHARMACEUTICALS, INC. Investment Income, Net
ALNYLAM PHARMACEUTICALS, INC. (ALNY) reported Investment Income, Net of $5.48 million for the 3-month period ending 2020-03-31, per its 10-Q filed 2020-05-06.
Discontinued › Income Statement › Other Income
us-gaap:InvestmentIncomeNet · last filed 2020-05-06
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2020-03-31 was $5.48M, a 27.18% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2019-12-31 was $7.25M, a 31.39% decline year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2019-09-30 was $9.89M, a 45.51% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for the quarter ending 2019-06-30 was $8.78M, a 43.93% increase year-over-year.
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for fiscal 2019 was $33.45M, a 14.31% increase from fiscal 2018.
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for fiscal 2018 was $29.26M, a 139.15% increase from fiscal 2017.
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for fiscal 2017 was $12.24M, a 47.28% increase from fiscal 2016.
- ALNYLAM PHARMACEUTICALS, INC. investment income, net for fiscal 2016 was $8.31M, a 41.80% increase from fiscal 2015.
| Period end | Investment Income, Net 3 month | Investment Income, Net 6 month | Investment Income, Net 9 month | Investment Income, Net 12 month |
|---|---|---|---|---|
| 2020-03-31 | $5.48M 10-Q · filed 2020-05-06 | $12.73M derived: sum of 2 quarters · filed 2020-05-06 | $22.62M derived: sum of 3 quarters · filed 2020-05-06 | $31.40M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-12-31 | $7.25M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $17.14M derived: sum of 2 quarters · filed 2020-02-13 | $25.92M derived: sum of 3 quarters · filed 2020-02-13 | $33.45M 10-K · filed 2020-02-13 |
| 2019-09-30 | $9.89M 10-Q · filed 2019-10-31 | $18.67M derived: sum of 2 quarters · filed 2019-10-31 | $26.20M 10-Q · filed 2019-10-31 | $36.77M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-06-30 | $8.78M 10-Q · filed 2019-08-06 | $16.31M 10-Q · filed 2019-08-06 | $26.88M derived: sum of 3 quarters · filed 2020-05-06 | $33.67M derived: sum of 4 quarters · filed 2020-05-06 |
| 2019-03-31 | $7.53M 10-Q · filed 2020-05-06 | $18.10M derived: sum of 2 quarters · filed 2020-05-06 | $24.89M derived: sum of 3 quarters · filed 2020-05-06 | $30.99M derived: sum of 4 quarters · filed 2020-05-06 |
| 2018-12-31 | $10.57M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $17.37M derived: sum of 2 quarters · filed 2020-02-13 | $23.47M derived: sum of 3 quarters · filed 2020-02-13 | $29.26M 10-K · filed 2020-02-13 |
| 2018-09-30 | $6.80M 10-Q · filed 2019-10-31 | $12.90M derived: sum of 2 quarters · filed 2019-10-31 | $18.69M 10-Q · filed 2019-10-31 | $22.93M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-06-30 | $6.10M 10-Q · filed 2019-08-06 | $11.89M 10-Q · filed 2019-08-06 | $16.13M derived: sum of 3 quarters · filed 2020-02-13 | $19.43M derived: sum of 4 quarters · filed 2020-02-13 |
| 2018-03-31 | $5.79M 10-Q · filed 2019-05-02 | $10.03M derived: sum of 2 quarters · filed 2020-02-13 | $13.32M derived: sum of 3 quarters · filed 2020-02-13 | $15.90M derived: sum of 4 quarters · filed 2020-02-13 |
| 2017-12-31 | $4.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-13 | $7.53M derived: sum of 2 quarters · filed 2020-02-13 | $10.11M derived: sum of 3 quarters · filed 2020-02-13 | $12.24M 10-K · filed 2020-02-13 |
| 2017-09-30 | $3.30M 10-Q · filed 2018-11-07 | $5.87M derived: sum of 2 quarters · filed 2018-11-07 | $8.00M 10-Q · filed 2018-11-07 | $10.20M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-06-30 | $2.58M 10-Q · filed 2018-08-02 | $4.71M 10-Q · filed 2018-08-02 | $6.90M derived: sum of 3 quarters · filed 2019-02-14 | $9.11M derived: sum of 4 quarters · filed 2019-02-14 |
| 2017-03-31 | $2.13M 10-Q · filed 2018-05-04 | $4.33M derived: sum of 2 quarters · filed 2019-02-14 | $6.53M derived: sum of 3 quarters · filed 2019-02-14 | $8.62M derived: sum of 4 quarters · filed 2019-02-14 |
| 2016-12-31 | $2.20M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-14 | $4.40M derived: sum of 2 quarters · filed 2019-02-14 | $6.50M derived: sum of 3 quarters · filed 2019-02-14 | $8.31M 10-K · filed 2019-02-14 |
| 2016-09-30 | $2.20M 10-Q · filed 2017-11-07 | $4.30M derived: sum of 2 quarters · filed 2017-11-07 | $6.11M 10-Q · filed 2017-11-07 | $7.72M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-06-30 | $2.09M 10-Q · filed 2017-08-09 | $3.90M 10-Q · filed 2017-08-09 | $5.52M derived: sum of 3 quarters · filed 2018-02-15 | $7.13M derived: sum of 4 quarters · filed 2018-02-15 |
| 2016-03-31 | $1.81M 10-Q · filed 2017-05-05 | $3.43M derived: sum of 2 quarters · filed 2018-02-15 | $5.04M derived: sum of 3 quarters · filed 2018-02-15 | $6.66M derived: sum of 4 quarters · filed 2018-02-15 |
| 2015-12-31 | $1.62M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-15 | $3.23M derived: sum of 2 quarters · filed 2018-02-15 | $4.84M derived: sum of 3 quarters · filed 2018-02-15 | $5.86M 10-K · filed 2018-02-15 |
| 2015-09-30 | $1.61M 10-Q · filed 2016-11-03 | $3.23M derived: sum of 2 quarters · filed 2016-11-03 | $4.24M 10-Q · filed 2016-11-03 | $5.02M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-06-30 | $1.62M 10-Q · filed 2016-08-04 | $2.63M 10-Q · filed 2016-08-04 | $3.41M derived: sum of 3 quarters · filed 2017-02-15 | $4.17M derived: sum of 4 quarters · filed 2017-02-15 |
| 2015-03-31 | $1.01M 10-Q · filed 2016-05-04 | $1.79M derived: sum of 2 quarters · filed 2017-02-15 | $2.55M derived: sum of 3 quarters · filed 2017-02-15 | $3.24M derived: sum of 4 quarters · filed 2017-02-15 |
| 2014-12-31 | $780.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-15 | $1.53M derived: sum of 2 quarters · filed 2017-02-15 | $2.23M derived: sum of 3 quarters · filed 2017-02-15 | $2.56M 10-K · filed 2017-02-15 |
| 2014-09-30 | $753.00K 10-Q · filed 2015-11-09 | $1.45M derived: sum of 2 quarters · filed 2015-11-09 | $1.78M 10-Q · filed 2015-11-09 | $2.06M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-06-30 | $693.00K 10-Q · filed 2015-08-07 | $1.03M 10-Q · filed 2015-08-07 | $1.31M derived: sum of 3 quarters · filed 2016-02-12 | $1.60M derived: sum of 4 quarters · filed 2016-02-12 |
| 2014-03-31 | $333.00K 10-Q · filed 2015-05-08 | $618.00K derived: sum of 2 quarters · filed 2016-02-12 | $908.00K derived: sum of 3 quarters · filed 2016-02-12 | $1.18M derived: sum of 4 quarters · filed 2016-02-12 |
| 2013-12-31 | $285.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-12 | $575.00K derived: sum of 2 quarters · filed 2016-02-12 | $845.00K derived: sum of 3 quarters · filed 2016-02-12 | $1.07M 10-K · filed 2016-02-12 |
| 2013-09-30 | $290.00K 10-Q · filed 2014-11-06 | $560.00K derived: sum of 2 quarters · filed 2014-11-06 | $784.00K 10-Q · filed 2014-11-06 | $1.01M derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-06-30 | $270.00K 10-Q · filed 2014-08-08 | $494.00K 10-Q · filed 2014-08-08 | $716.00K derived: sum of 3 quarters · filed 2015-02-13 | $977.00K derived: sum of 4 quarters · filed 2015-02-13 |
| 2013-03-31 | $224.00K 10-Q · filed 2014-05-09 | $446.00K derived: sum of 2 quarters · filed 2015-02-13 | $707.00K derived: sum of 3 quarters · filed 2015-02-13 | $978.00K derived: sum of 4 quarters · filed 2015-02-13 |
| 2012-12-31 | $222.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-13 | $483.00K derived: sum of 2 quarters · filed 2015-02-13 | $754.00K derived: sum of 3 quarters · filed 2015-02-13 | $977.00K 10-K · filed 2015-02-13 |
| 2012-09-30 | $261.00K 10-Q · filed 2013-11-07 | $532.00K derived: sum of 2 quarters · filed 2013-11-07 | $755.00K 10-Q · filed 2013-11-07 | |
| 2012-06-30 | $271.00K 10-Q · filed 2013-08-09 | $494.00K 10-Q · filed 2013-08-09 | ||
| 2011-12-31 | $1.21M 10-K · filed 2014-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |